?

Doogan Declan

Director
Tenax Therapeutics, Inc.
US, Morrisville [HQ]
CIK 1704234

Data Source

We automatically created this profile. The information was aggregated based on earnings call transcripts, insider forms and DEF 14A statements.

Latest Information

Shares :
3,637,871
Price per Share :
$6.48
Equivalence :
$23,573,404.08

Transaction History

  • M
    Form 4
    3,637,871 Shares After Transaction
    Value : $n/a
    $0.0
    06/11/21
  • Footnotes:
    #1 On June 10, 2021, the shareholders of Tenax Therapeutics, Inc. voted in favor of the conversion of all Series B Preferred Stock to Common Stock. Pursuant to this action, all Series B Preferred Stock owned by the Reporting Person converted automatically to shares of Common Stock on June 11, 2021.
    #2 As described further in Note 1, above, the disposition of the Series B Preferred Stock and the acquisition of Common Stock occurred pursuant to an automatic conversion; as such, no consideration was paid to or payable by the Reporting Person pursuant to this transaction.
  • G
    Form 4
    2,502,129 Shares After Transaction
    Value : $n/a
    $0.0
    06/30/21
  • G
    Form 4
    0.0 Shares After Transaction
    Value : $n/a
    $0.0
    08/11/22
  • G
    Form 4
    3,637,871 Shares After Transaction
    Value : $n/a
    $0.0
    08/11/22